| Ytd | -37.55% | |
| 1y | -40.89% |
| Open | 11.48 | Prev Close | 11.34 | Low | 11.22 | High | 11.49 | Mkt Cap | 2.83B |
| Vol | 1.40M | Avg Vol | 2.96M | EPS | 0.23 | P/E | 48.96 | Forward P/E | 17.24 |
| Beta | 1.13 | Short Ratio | 2.76 | Inst. Own | 51.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 12.19 | 200-d Avg | 13.94 | 1yr Est | 15.36 |
CLBT News
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
Boston, Massachusetts--(Newsfile Corp. - October 2, 2026) - Block & Leviton is investigating Cellebr
New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigatin
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
Cellebrite maintains a strong competitive moat through deep integration with government and law enfo
New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Law&Crime Network and NewsNation anchor Jesse Weber returns to host; ceremony to stream live to Law&
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investiga
Squarepoint Ops LLC lessened its stake in Cellebrite DI Ltd. (NASDAQ: CLBT) by 49.8% in the undefine
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), ein weltweit führender Anbieter von KI-gestützten
/PRNewswire/ -- Cellebrite DI Ltd. (Nasdaq: CLBT), leader mondial des solutions d'enquête et de rens
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers t
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers th
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Gainers BGIN Blockchain (NASDAQ:BGIN) stock rose 38.8% to $2.36 during Thursday's regular sessi
Shares of Cellebrite are trading sharply lower on Thursday following the release of second-quarter f
US stocks mixed, Nasdaq up more than 150 points. Dow down 0.16% to 53,682.87, Nasdaq up 0.61% to 26,
Cellebrite DI (NASDAQ:CLBT) reported second-quarter financial results on Thursday. The transcript fr
US stocks up, Dow gains over 100 points. Real estate sector rises, energy sector falls. Producer Pri
Gainers Yxt.Com Group Holding (NASDAQ:YXT) stock moved upwards by 47.5% to $6.68 during Thursday
Cellebrite DI (NASDAQ:CLBT) lowers FY2026 sales outlook from $565.000 million-$571.000 million to $5
Cellebrite DI (NASDAQ:CLBT) sees Q3 sales of $145.000 million-$148.000 million vs $150.298 million a
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.11 per share which met the analyst con
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises th
DA Davidson analyst Rudy Kessinger initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy r
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in AI-powered Digital Investigative and Intelligen
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price
Cellebrite DI (NASDAQ:CLBT) sees FY2026 sales of $565.000 million-$571.000 million vs $554.864 milli
Cellebrite DI (NASDAQ:CLBT) sees Q1 sales of $126.000 million-$128.000 million vs $130.637 million a
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.14 per share which met the analyst con
Needham analysts met with 12 companies before quiet period. Ratings and price targets by analyst Mik
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and raises
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises t